Wayne Paterson

President and CEO

Wayne has held numerous, senior positions in multi-national companies and has lived in seven countries during the past 25 years. Through his career, he has been responsible for building and managing multibillion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO.

From 2005 to 2013 he held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular medicine.

Between 1999 and 2005, Wayne served at Roche Pharmaceuticals where he was Head of Pharmaceuticals in Roche’s South Korean operation, following his role as Head of Commercial Operations for Roche China based in Shanghai.

From April 2015 until November 2016, Wayne served as a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California.
He holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology.

He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.

John Seaberg


Between 2007 and 2014, John was Founder, Chairman and CEO of NeoChord Inc, a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.

Previously, John served at Guidant Corp from 1996 until 2006. During ten years at Guidant, he served in various executive level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management (CRM) and Vice President of Sales for Cardiac Surgery, in which he managed a field sales team of more than 600 people and over $1 billion in revenue.

In 1991, John co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices. He lives in Minneapolis and holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

Stephen Denaro

Non-Executive Director and Company Secretary

Stephen has extensive experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of various public companies and with major chartered accountancy firms in Australia and the United Kingdom. He provides company secretarial services for a number of start-up technology, ASX listed (Anatara Lifesciences Limited “ASX: ANR” and Oventus Medical Limited “ASX: OVN”) and unlisted public companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not for profit company, National Affordable Housing Consortium Limited.

Stephen has a Bachelor of Business in Accountancy, Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Accountants in Australia & New Zealand, and the Australian Institute of Company Directors.

Wenyi Gu

Non Executive Director

Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland (UQ) where he began his post-doctoral work in 2001.

Dr Gu holds a master’s degree in veterinary science and completed his PhD study in biochemistry and molecular biology at Australian National University (ANU) and later worked at John Curtin Medical School (ANU). He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting fellow.

Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translational Research Institute (TRI).

Dr Gu’s research has been extensively published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd.

Dr Yanheng Wu

Non-Executive Director

Dr Wu currently serves as President and Managing Director of Constellation International Group Holdings Ltd. Dr Wu also established the Guangzhou Hearty-Care Biotechnology Ltd, a medical technology company.

Dr Wu completed his PhD in tumour immunotherapy and nanocarrier technology at The University of Queensland. He holds multiple biomedical patents and is well published domestically and internationally.

Before commencing his PhD, he worked at Sun Yat-sen University Cancer Center as a researcher. He also holds a Bachelor of Clinical Medicine from Guangzhou Medical University.